Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
Affected Genes

Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Ratio Regulation description Class Gene Ontology Gene Accession Minimum Ratio Maximum Ratio
Results: HTML CSV LaTeX
Showing element 1 to 50 of 103 in total
Class: molecular function
Gene Ontology: protein binding

\def\wcA{0.25\textwidth}
\def\wcB{0.25\textwidth}
\def\wcC{0.25\textwidth}
\begin{longtable}{|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Ratio\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Regulation\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.08658\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
pyrin and HIN domain family, member 1 alpha 1 isoform \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.13541\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Protein kinase C-binding protein NELL2 precursor (NEL-like protein 2) (Nel-related protein 2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.15279\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Podocalyxin-like protein 2 precursor (Endoglycan). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.16499\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
ADAM 22 precursor (A disintegrin and metalloproteinase domain 22) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 2) (Metalloproteinase-disintegrin ADAM22-3). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.16823\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
S-phase kinase-associated protein 2 (F-box protein Skp2) (Cyclin A/CDK2-associated protein p45) (p45skp2) (F-box/LRR-repeat protein 1). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.18096\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Prostaglandin G/H synthase 2 precursor (EC 1.14.99.1) (Cyclooxygenase- 2) (COX-2) (Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.18711\vspace{3pt}}&\multirow{7}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
NULL\vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.19117\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Ras-related GTP-binding protein D (Rag D). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.19207\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Nuclear RNA export factor 2 (TAP-like protein 2) (TAPL-2). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.19545\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Deoxyribonuclease-2-alpha precursor (EC 3.1.22.1) (Deoxyribonuclease II alpha) (DNase II alpha) (Acid DNase) (Lysosomal DNase II) (R31240\_2). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.21657\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Septin-5 (Peanut-like protein 1) (Cell division control-related protein 1) (CDCrel-1). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.21698\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Kelch-like protein 34. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.21705\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
T-complex protein 1 subunit beta (TCP-1-beta) (CCT-beta). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.21871\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Bcl-2-interacting killer (Apoptosis inducer NBK) (BP4) (BIP1). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.22178\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Serine/threonine-protein kinase PFTAIRE-1 (EC 2.7.11.22). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.22576\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Methyl-CpG-binding domain protein 1 (Methyl-CpG-binding protein MBD1) (Protein containing methyl-CpG-binding domain 1). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.23845\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Insulin-induced gene 1 protein (INSIG-1). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.24964\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Atlastin-2 (ADP-ribosylation factor-like protein 6-interacting protein 2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.25147\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
T-lymphocyte activation antigen CD86 precursor (Activation B7-2 antigen) (CTLA-4 counter-receptor B7.2) (B70) (FUN-1) (BU63). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.2734\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Neurexin-2-alpha precursor (Neurexin II-alpha). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.27696\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Speedy protein A (Speedy-1) (Spy1) (Rapid inducer of G2/M progression in oocytes A) (RINGO A) (hSpy/Ringo A). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.27802\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Melanoma-associated antigen B2 (MAGE-B2 antigen) (DSS-AHC critical interval MAGE superfamily 6) (DAM6) (MAGE XP-2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.28319\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Autophagy-related protein 10 (APG10-like). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.28356\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
T-box transcription factor TBX2 (T-box protein 2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.29151\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
CLIP-associating protein 2 (Cytoplasmic linker-associated protein 2) (hOrbit2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.30207\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low density lipoprotein receptor adapter protein 1 (Autosomal recessive hypercholesterolemia protein). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.30869\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
E3 ubiquitin-protein ligase CHFR (EC 6.3.2.-) (Checkpoint with forkhead and RING finger domains protein) (RING finger protein 196). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.31489\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Tripartite motif-containing protein 58 (Protein BIA2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.33465\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
T-box transcription factor TBX5 (T-box protein 5). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.33817\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABA(A) receptor-associated protein-like 1) (Glandular epithelial cell protein 1) (GEC-1) (Early estrogen-regulated protein). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.34969\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
MAP/microtubule affinity-regulating kinase 3 (EC 2.7.11.1) (Cdc25C- associated protein kinase 1) (cTAK1) (C-TAK1) (Serine/threonine protein kinase p78) (Ser/Thr protein kinase PAR-1) (Protein kinase STK10). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.35022\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
N-glycosylase/DNA lyase [Includes: 8-oxoguanine DNA glycosylase (EC 3.2.2.-); DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP lyase)]. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.35125\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Geminin. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.36997\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Rho GTPase-activating protein 24 (Rho-type GTPase-activating protein 24) (Filamin-A-associated RhoGAP) (FilGAP) (p73RhoGAP) (RhoGAP of 73 kDa) (RAC1- and CDC42-specific GTPase-activating protein of 72 kDa) (RC-GAP72) (Sarcoma antigen NY-SAR-88). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.40093\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
NULL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.42215\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Sodium-dependent serotonin transporter (5HT transporter) (5HTT). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.44789\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
POU domain class 2-associating factor 1 (B-cell-specific coactivator OBF-1) (OCT-binding factor 1) (BOB-1) (OCA-B). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.45148\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Golgin subfamily B member 1 (Giantin) (Macrogolgin) (372 kDa Golgi complex-associated protein) (GCP372). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.45635\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Cyclin-A2 (Cyclin-A). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.4628\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Poliovirus receptor-related protein 3 precursor (Nectin-3) (CD113 antigen) (CDw113). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.48363\vspace{3pt}}&\multirow{8}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Wee1-like protein kinase (EC 2.7.10.2) (Wee1A kinase) (WEE1hu). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.48389\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Nuclear pore complex protein Nup153 (Nucleoporin Nup153) (153 kDa nucleoporin). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.49271\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Cullin-4B (CUL-4B). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.49558\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Bone morphogenetic protein 2 precursor (BMP-2) (BMP-2A). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.49923\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Rap guanine nucleotide exchange factor 1 (Guanine nucleotide-releasing factor 2) (C3G protein) (CRK SH3-binding GNRP). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.50284\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
AP-3 complex subunit sigma-2 (Adapter-related protein complex 3 sigma- 2 subunit) (Sigma-adaptin 3b) (AP-3 complex sigma-3B subunit) (Sigma- 3B-adaptin). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.50715\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
F-box/WD repeat protein 5 (F-box and WD-40 domain protein 5). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.58045\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Peroxisomal biogenesis factor 3 (Peroxin-3) (Peroxisomal assembly protein PEX3). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.59177\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Transgelin-2 (SM22-alpha homolog). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.61347\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Calmodulin-like protein 5 (Calmodulin-like skin protein). \vspace{3pt}}\\\hline
nd{longtable}

Legend:
- The Ratio specifies how much this gene is up/down regulated. When up- or down-regulated must this value respectively be multiplied/divided to obtain the MK5 on concentration based on the MK5 off concentration.

 - The Regulation specifies how this gene is affected when going from the MK5 off cells to the MK5 on cells. 

 - The Class refers to the ontology category, which can be molecular_function, biological_process or cellular_component. 

 - The Gene Ontology terms as linked to the specific gene.

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Accession is the GO accession key. 

 - Minimum Ratio is the lowest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

 - Maximum Ratio is the highest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.
- http://analysis.yellowcouch.org/